Sydney Jennings

Your daily dose of the clinical news you may have missed.

JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.

Your daily dose of the clinical news you may have missed.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

Your daily dose of the clinical news you may have missed.

FluMist is the first influenza vaccine that does not have to be given by a health care professional.

New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

Your daily dose of the clinical news you may have missed.

New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

Your daily dose of the clinical news you may have missed.

In a study of patients with atopic dermatitis, tralokinumab was effective and safe in elderly patients and those with severe comorbidities.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In a study of patients with CHE, 75.5% of participants totally or almost agreed that topical corticosteroids cause damage to skin.

Your daily dose of the clinical news you may have missed.

ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.

Your daily dose of the clinical news you may have missed.

The updated COVID-19 vaccine targets the currently circulating Omicron variant JN.1 strain of SARS-CoV-2.

Your daily dose of the clinical news you may have missed.